CYP2C19 rs12248560: what the research says
rs12248560
Pharmacogenomics
Moderate evidenceGene: CYP2C19CYP2C19*17 increased-expression variant associated with ultrarapid metabolism of drugs such as clopidogrel, escitalopram, and voriconazole.
Our full long-form research profile for rs12248560 — genotype interpretations, evidence review, and FAQ — is being written and will appear on this page soon.
Curious what your genotype is for rs12248560?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in CYP2C19
rs17222419
CYP2C19Trait
ModerateNon-functional allele that causes poor metabolism of clopidogrel and PPIs.
rs28365045
CYP2C19Pharmacogenomics
ModerateThis variant is linked to the loss of function in the CYP2C19 enzyme, affecting clopidogrel efficacy.
rs4244285
CYP2C19Pharmacogenomics
StrongCYP2C19*2 loss-of-function variant reduces clopidogrel activation; carriers may have poorer platelet inhibition and higher cardiovascular event risk.
rs4986894
CYP2C19Pharmacogenomics
StrongCYP2C19*3 stop-gain variant abolishes CYP2C19 activity; combined with *2 it defines poor-metabolizer status for clopidogrel.